Amanta Healthcare IPO GMP made a high of ₹23 on 27 August, while it hit a low of ₹21 on 26 August.
Check out Amanta Healthcare IPO GMP (which is IPO grey market premium), Kostak rates and today's subject to deal rates. Amanta Healthcare IPO has just launched. Stay tuned for the latest IPO GMP data of Amanta Healthcare IPO.
Amanta Healthcare IPO will open on 1 September. Amanta Healthcare is a mainboard IPO that will raise ₹126 crore through IPO. The price band of Amanta Healthcare IPO is fixed at ₹120 to ₹126 and its market lot is 119 shares.
Amanta Healthcare Limited, established in December 1994, is one of the leading pharmaceutical companies engaged in the development, manufacturing and marketing of a wide range of sterile liquid products, primarily parenteral. These are packaged in plastic containers using advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Molding (ISBM) technologies. The fluid therapy products manufactured by the company include IV fluids, diluents, eye drops and respiratory care solutions.
Amanta Healthcare IPO Details
| IPO Open Date: | September 1, 2025 |
| IPO Close Date: | September 3, 2025 |
| Face Value: | ₹10 Per Equity Share |
| IPO Price Band: | ₹120 to ₹126 Per Share |
| Issue Size: | Approx ₹126 Crores |
| Fresh Issue: | Approx ₹126 Crores |
| Lot Size: | 119 Shares |
| Issue Type: | Book Built Issue |
| IPO Listing: | BSE & NSE |
| Retail Quota: | Not more than 35% |
| QIB Quota: | Not more than 50% |
| NII Quota: | Not more than 15% |
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | Click Here |
| Anchor Investors List: | Click Here |
Amanta Healthcare IPO Dates
| IPO Open Date: | September 1, 2025 |
| IPO Close Date: | September 3, 2025 |
| Basis of Allotment: | September 4, 2025 |
| Refunds: | September 5, 2025 |
| Credit to Demat Account: | September 5, 2025 |
| IPO Listing Date: | September 8, 2025 |
Amanta Healthcare Financial Report
The company reported revenue of ₹276 crores in 2025 against ₹282 crores in 2024. The company reported profit of ₹10.50 crores in 2025 against profit of ₹3.63 crores in 2024.
Amount ₹ in Crores
| Period Ended | Revenue | Expense | PAT | Assets |
| 2023 | ₹263 | ₹206 | ₹2.11 | ₹374 |
| 2024 | ₹282 | ₹223 | ₹3.63 | ₹352 |
| 2025 | ₹276 | ₹215 | ₹10.50 | ₹382 |
Amanta Healthcare IPO Valuation – FY2025
Check Amanta Healthcare IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | 12.42% |
| ROCE: | 13.72% |
| EBITDA Margin: | 22.11% |
| PAT Margin: | 3.86% |
| Debt to equity ratio: | 2.02 |
| Earning Per Share (EPS): | ₹3.71 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 10.89% |
| Net Asset Value (NAV): | ₹33.43 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Denis Chem Lab Limited | 5.82 | 15.92 | 9.49% | 61.33 | 176 Cr. |
Promoters of Amanta Healthcare
The promoters of the company are Bhavesh Patel, Vishal Patel, Jayshreeben Patel, Jitendra Kumar Patel and Milcent Appliances Private Limited.
Business Overview
Amanta Healthcare Limited, founded in December 1994, is one of the leading pharmaceutical companies that is involved in the development, manufacturing, and marketing of a wide range of sterile liquid products, mainly parenterals. These are packed in plastic containers using advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies. IV fluids, diluents, eye drops, and respiratory care solutions are some of the fluid therapy products that the company makes.
Amanta Healthcare also produces irrigation solutions, first-aid items, and eye lubricants under its medical devices segment. The company markets its products through three business divisions: National Sales, International Sales, and Product Partnerships with various Indian and foreign pharmaceutical companies. Under its own brand, the company makes over 45 generic products and sells them in India, through 320 distributors and stockists. The company employs a total of 1,718 employees as of March 31, 2025.
Objects of the Issue
- Funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat
- Funding capital expenditure requirements towards civil construction work, purchase of equipment, plant and machinery for setting up new manufacturing line for SVP at Hariyala, Kheda, Gujarat